1. Papoiu AD, Yosipovitch G: Topical
capsaicin. The fire of a “hot” medicine is reignited.
Expert Opin Pharmacother 11:1359-1371, 2010
2. Backonja MM et al: NGX-4010, a high-concentration
capsaicin patch, for the treatment of postherpetic neuralgia: A randomized, double-blind, controlled study with an open-label extension.
Pain Med 11:600-608, 2010
3. Tyring SK: Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 57:S136-S142, 2007
4. Kaweski S: Topical anesthetic creams. Plast Reconstr Surg 121:2161-2165, 2008
5. Briggs M, Nelson EA: Topical agents or dressings for pain in venous leg ulcers. Cochrane Database Syst Rev 4:CD001177, 2010
6. Guay J: Methemoglobinemia related to local anesthetics: A summary of 242 episodes. Anesth Analg 108:837-845, 2009
7. Marra DE et al: Systemic toxicity from topically applied
lidocaine in conjunction with fractional photothermolysis.
Arch Dermatol 142:1024-1026, 2006
8. Public Health Advisory: Life-threatening side effects with the use of skin products containing numbing ingredients for cosmetic procedures [Internet]. FDA: Rockville, MD, http://www.fda.gov/Drugs/DrugSafety/PublicHealth Advisories/ucm054718.htm, accessed Feb 6, 2007 [cited Jul 8, 2010]
10. Paghdal KV, Schwartz RA: Topical tar: Back to the future. J Am Acad Dermatol 61:294-302, 2009
11. Stoughton RB, DeQuoy P, Walter JF: Crude coal tar plus near ultraviolet light suppresses DNA synthesis in epidermis. Arch Dermatol 114:43-45, 1978
12. Alora-Palli MB et al: Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: A controlled comparison with
calcipotriene (calcipotriol) cream.
Am J Clin Dermatol 11:275-283, 2010
13. Brouda I et al: Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis. Cutis 85:214-220, 2010
14. Maughan WZ et al: Incidence of skin cancers in patients with atopic dermatitis treated with ocal tar. A 25-year follow-up study. J Am Acad Dermatol 3:612-615, 1980
15. Saap L et al: Contact sensitivity in patients with leg ulcerations: A North American study. Arch Dermatol 140:1241-1246, 2004
16. Warnecke J, Wendt A: Anti-inflammatory action of pale sulfonated shale oil (ICHTHYOL pale) in UVB erythema test. Inflamm Res 47:75-78, 1998
17. Schewe C et al: Inhibitory effects of sulfonated shale oils (ammonium bituminosulphonates, Ichthyols) on enzymes of polyenoic fatty acid metabolism. Arch Dermatol Res 286:137-141, 1994
18. Korting HC et al: Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: A multicentre, randomized vehicle-controlled trial. J Eur Acad Dermatol Venereol 24(10):1176-1182, 2010
19. Beckert S et al: Efficacy of topical pale sulfonated shale oil in the treatment of venous leg ulcers: A randomized, controlled, multicenter study. J Vasc Surg 43:94-100, 2006
20. Schmid MH, Korting HC: Coal tar, pine tar and sulfonated shale oil preparations: Comparative activity, efficacy and safety. Dermatology 193:1-5, 1996
21. Balabanova M, Popova L, Tchipeva R: Dyes in dermatology. Clin Dermatol 21:2-6, 2003
22. Tsubaki T, Honma Y, Hoshi M: Neurological syndrome associated with clioquinol. Lancet 1:696-697, 1971
23. Meade TW: Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis. Br J Prev Soc Med 29:157-169, 1975
24. Lio PA, Kaye ET: Topical antibacterial agents. Infect Dis Clin North Am 23:945-63, ix, 2009
25. Koning S et al: Efficacy and safety of
retapamulin ointment as treatment of impetigo: Randomized double-blind multicentre placebo-controlled trial.
Br J Dermatol 158:1077-1082, 2008
26. Gollnick H, Layton A: Azelaic acid 15% gel in the treatment of rosacea. Expert Opin Pharmacother 9:2699-2706, 2008
27. Sagransky M, Yentzer BA, Feldman SR: Benzoyl peroxide: A review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother 10:2555-2562, 2009
28. Strong M, Johnstone PW: Interventions for treating scabies. Cochrane Database Syst Rev 2007:CD000320
29. Burkhart CG, Burkhart CN: Safety and efficacy of pediculicides for head lice. Expert Opin Drug Saf 5:169-179, 2006
30. Downs AM et al: Evidence for double resistance to
permethrin and
malathion in head lice.
Br J Dermatol 141:508-511, 1999
31. Roos
TC et al: Pharmacotherapy of ectoparasitic infections.
Drugs 61:1067-1088, 2001
32. American Academy of Pediatrics: Pediculosis capitis (head lice). In: Red Book 2009 Report of the Committee on Infectious Diseases, edited by LK Pickering. Elk Groove Village, IL, American Academy of Pediatrics, 2009, p. 495
33. Fisher AA: Contact Dermatitis, 3rd edition. Philadelphia, Lea & Febiger, 1986
34. Stough D et al: Efficacy and safety of
spinosad and
permethrin creme rinses for pediculosis capitis (head lice).
Pediatrics 124(3):e389-e395, 2009
35. Solish N et al: A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 33:908-923, 2007
36. Togel B, Greve B, Raulin C: Current therapeutic strategies for hyperhidrosis: A review. Eur J Dermatol 12:219-223, 2002
37. Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: Evolving therapies for a well-established phenomenon. Mayo Clin Proc 80:657-666, 2005
38. Kavanagh GM, Shams K: Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. J Am Acad Dermatol 55:S115-S117, 2006
39. Kavanagh GM, Oh C, Shams K: BOTOX delivery by iontophoresis. Br J Dermatol 151:1093-1095, 2004
40. Patel T, Ishiuji Y, Yosipovitch G: Menthol: A refreshing look at this ancient compound. J Am Acad Dermatol 57:873-878, 2007
41. Patel T, Yosipovitch G: Therapy of pruritus. Expert Opin Pharmacother 11:1673-1682, 2010
42. Code of Federal Regulations Title 21, Volume 5, Chapter I, Part 347—Skin Protectant Drug Products for Over-the-counter Human Use: Subpart A—Astringent Drug Products, pp. 270-271 [CITE: 21CFR347], revised as of Apr 1, 2002
43. Chou TD et al: Methemoglobinemia secondary to topical
silver nitrate therapy—A case report.
Burns 25:549-552, 1999
44. Rendon M et al: Treatment of melasma. J Am Acad Dermatol 54:S272-S281, 2006
45. Grimes PE et al: Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol 62:962-967, 2010
46. Department of Health and Human Services, Food and Drug Administration:
Skin Bleaching Drug Products for Over-the-Counter Human Use: Proposed Rule. Federal Register Aug 29, 2006 (Vol. 71, No. 167, pp. 51146-51155),
http://www.fda.gov/ohrms/dockets/98fr/e6-14263.htm, accessed Jul 8, 2010
47. Levitt J: The safety of
hydroquinone: A dermatologist's response to the 2006 Federal Register.
J Am Acad Dermatol 57:854-872, 2007
49. Katz KA: Topical
tretinoin, lung cancer, and lung-related mortality.
Arch Dermatol 144:945-946, 2008
50. Schilling LM, Dellavalle RP: Dealing with unanticipated mortality in a large randomized clinical trial of topical
tretinoin.
Arch Dermatol 145:76, 2009
51. Powers W, Jr., Shapiro SS, Heremans A:
Tretinoin: An established long-term safety profile.
Arch Dermatol 145:1063-1064, 2009; author reply 4-5
52. Weinstock MA et al: Topical
tretinoin therapy and all-cause mortality.
Arch Dermatol 145:18-24, 2009
53. Hariharan V et al: Monobenzyl ether of
hydroquinone and 4-tertiary butyl
phenol activate markedly different physiological responses in melanocytes: Relevance to skin depigmentation.
J Invest Dermatol 130:211-220, 2010
54. Ganemo A, Virtanen M, Vahlquist A: Improved topical treatment of lamellar ichthyosis: A double-blind study of four different cream formulations. Br J Dermatol 141:1027-1032, 1999
55. Lin AN, Nakatsui T: Salicylic acid revisited. Int J Dermatol 37:335-342, 1998
56. Wohlrab W: The influence of urea on the penetration kinetics of topically applied corticosteroids. Acta Derm Venereol 64:233-238, 1984
57. Rawlings AV et al: Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function. Arch Dermatol Res 288:383-390, 1996
58. Ashcroft DM et al: Combination regimens of topical
calcipotriene in chronic plaque psoriasis: Systematic review of efficacy and tolerability.
Arch Dermatol 136:1536-1543, 2000
59. Mason J, Mason AR, Cork MJ: Topical preparations for the treatment of psoriasis: A systematic review. Br J Dermatol 146:351-364, 2002
60. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of
calcipotriene plus
betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial.
J Am Acad Dermatol 59:455-463, 2008
61. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 60:643-659, 2009
62. Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol 145:385-405, 2001
63. Gibbs S, Harvey I: Topical treatments for cutaneous warts. Cochrane Database Syst Rev 3:CD001781, 2006
64. Tatti S et al:
Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: A randomized controlled trial.
Obstet Gynecol 111:1371-1319, 2008
65. Tatti S et al: Polyphenon E: A new treatment for external anogenital warts. Br J Dermatol 162:176-184, 2010